Oncology Central

Current therapies for HNC: why is immunotherapy not yet in the forefront?


Despite substantial, even impressive, recent advances in the detection and therapy of head and neck cancer (HNC), morbidity and mortality attributable to this disease remain high throughout the world. Today, head and neck squamous cell carcinomas are the sixth cause of cancer deaths worldwide [1]. In the USA, more than 52,000 new cases of head and neck squamous cell carcinomas are reported per year, with approximately 12,000 deaths [101].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.